2021
DOI: 10.1099/jgv.0.001539
|View full text |Cite
|
Sign up to set email alerts
|

Assessment of inactivation procedures for SARS-CoV-2

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), presents a challenge to laboratorians and healthcare workers around the world. Handling of biological samples from individuals infected with the SARS-CoV-2 virus requires strict biosafety measures. Within the laboratory, non-propagative work with samples containing the virus requires, at minimum, Biosafety Level-2 (BSL-2) techniques and facilities. Therefore, handling of SARS-CoV-2 samples … Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
46
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
3

Relationship

2
8

Authors

Journals

citations
Cited by 51 publications
(49 citation statements)
references
References 35 publications
1
46
0
Order By: Relevance
“…Searching for a solution capable of stabilizing SARS-CoV-2 RNA in saliva, we initially screened six formulations containing Proteinase K (namely PK1-6). AVL, a commercial guanidine-based buffer recommended for SARS-CoV-2 inactivation [10], was used as the experimental control, without any heat treatment. Since unprotected viral RNA is rapidly degraded in crude saliva, we simulated samples by first mixing saliva from a healthy donor with the solutions (1:1, v/v) and heating at 65 • C for 15 min followed by a step at 95 • C for 2 min, before spiking in SARS-CoV-2 RNA.…”
Section: Stabilization Of Sars-cov-2 Rna In Salivamentioning
confidence: 99%
“…Searching for a solution capable of stabilizing SARS-CoV-2 RNA in saliva, we initially screened six formulations containing Proteinase K (namely PK1-6). AVL, a commercial guanidine-based buffer recommended for SARS-CoV-2 inactivation [10], was used as the experimental control, without any heat treatment. Since unprotected viral RNA is rapidly degraded in crude saliva, we simulated samples by first mixing saliva from a healthy donor with the solutions (1:1, v/v) and heating at 65 • C for 15 min followed by a step at 95 • C for 2 min, before spiking in SARS-CoV-2 RNA.…”
Section: Stabilization Of Sars-cov-2 Rna In Salivamentioning
confidence: 99%
“…To control for extensive variation in qPCR test and target (each of which reported varying thresholds for positivity), we carried out in vitro experiments using SARS-CoV-2 isolates from infected patients reporting similar Ct values on the TaqPath platform at the time of sampling. Briefly, three SARS-CoV-2 isolates (designated hCoV-19/Madagascar/IPM-00754/2021, hCoV-19/Madagascar/IPM-01263/2021 and hCoV-19/Madagascar/IPM-01315/2021) were obtained and cultured in Vero cells as previously described [34]. Upon infection with SARS-CoV-2, the culture medium was replaced by infection medium containing DMEM, 5 % FBS, antibiotics, 2.5 μg/ml Amphotericin B (Gibco) and 16 μg/ml TPCK-trypsin (Gibco).…”
Section: Standardizing Ct Values Across Tests and Targetsmentioning
confidence: 99%
“…Moreover, samples with high viral load pose a risk of infection for the handler. Heat treatment of viral particles has been shown effective in inactivating SARS-CoV-2 with 70˚C 5min treatment rendering viral infectivity undetectable employing Vero E6 cells (limit of detection of TCID50 assay was 100 TCID50/mL) [18][19][20]. Other heat treatment protocols have also been demonstrated, with variable effects on PCR sensitivity [21].…”
Section: Heat Inactivation Comparisonmentioning
confidence: 99%